Your Complete BMI Requirements & Starter Dose Guide
Understanding Wegovy BMI Requirements for New Patients
Wegovy BMI requirements are clearly defined by MHRA licensing and NICE guidelines to ensure this prescription-only medicine reaches patients who can benefit most. Adults need a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnoea. The 0.25mg starter dose is mandatory for all patients meeting these Wegovy BMI requirements, regardless of your current weight or BMI level.
Starting with the correct dose escalation schedule is essential for minimising side effects while allowing your body to adjust to semaglutide gradually. Many patients wonder if they can begin with higher doses to accelerate results, but clinical evidence demonstrates that following the prescribed 16-week escalation protocol optimises both tolerability and long-term success. This careful approach to meeting Wegovy BMI requirements and dose progression reflects the rigorous clinical trial methodology that proved the medication's effectiveness.
Starter Dose Pricing and Bundle Options
The 0.25mg starter dose costs £79.99 for a 4-week supply, representing the most affordable entry point for patients meeting Wegovy BMI requirements. New customers can apply discount code FIRST40 at checkout to reach this price, while returning customers use code DOSE25 for ongoing savings. For those planning ahead, our Intro Duo bundle combines the 0.25mg starter with the subsequent 0.5mg dose for £169.99, providing your first 8 weeks of treatment in one convenient order.
Our Gentle Start Trio bundle offers an alternative approach for patients concerned about side effects, featuring two 0.25mg pens plus one 0.5mg pen for £269.99. This allows you to spend longer at the starter dose if needed while still progressing through your weight management programme. All prices include next-day delivery and support from our clinical team, ensuring you receive comprehensive care alongside your medication.
Clinical Evidence Supporting Wegovy BMI Requirements
The STEP clinical trial programme established the foundation for current Wegovy BMI requirements and dosing protocols. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. Importantly, all participants began with the same 0.25mg starter dose regardless of their baseline BMI or weight.
Long-term data from STEP 5 demonstrated that patients maintained approximately clinically studied weight loss at two years, confirming the importance of proper dose initiation in achieving sustained results. The SELECT cardiovascular outcomes trial further validated the health benefits, showing a 20% reduction in major cardiovascular events with hazard ratio 0.80, supporting the clinical rationale behind Wegovy BMI requirements.
How Wegovy Works for BMI-Eligible Patients
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and blood sugar levels. When you inject the weekly dose, semaglutide binds to GLP-1 receptors in your brain's appetite control centres, potentially reducing food cravings and promoting earlier feelings of fullness during meals. The medication may also slow gastric emptying, helping smaller meals feel more satisfying for longer periods. This mechanism explains why the 0.25mg starter dose can produce noticeable appetite changes within the first few weeks, even before reaching higher maintenance doses. For patients meeting Wegovy BMI requirements, this gradual appetite modification supports sustainable behaviour changes rather than dramatic dietary restrictions.
Simple Ordering Process for BMI-Eligible Patients
Beginning your Wegovy journey starts with our 3-minute online clinical assessment, which evaluates your BMI alongside other eligibility criteria including current medications and weight-related health conditions. Our prescribers typically complete their review within 3 working days, though express 24-hour review is available for urgent cases. Once approved, your 0.25mg starter dose ships via next-day delivery using temperature-controlled packaging to maintain the medication's effectiveness. The entire process from assessment to delivery usually takes 4-5 days, ensuring you can begin treatment quickly while maintaining all necessary safety protocols. Our GPhC-registered pharmacy (#9012878) handles every step of the process, providing both regulatory compliance and clinical support throughout your treatment.
Practical Storage and Administration Guidance
Your Wegovy starter dose arrives in Novo Nordisk's FlexTouch pen, pre-loaded with 0.25mg doses for 4 weekly injections. Store the pen in your fridge at 2-8°C until first use, after which it remains effective at room temperature for up to 6 weeks - significantly longer than competing medications. Inject once weekly on the same day, rotating between your abdomen, thigh, or upper arm to prevent injection site reactions. The pen's dose counter clearly displays each 0.25mg dose, while the simple click-mechanism makes administration straightforward even for injection-nervous patients. Remember that completing the full 4-week starter period is essential before progressing to 0.5mg, regardless of your initial response or side effects.
Wegovy BMI Requirements vs Real-World Eligibility
While official Wegovy BMI requirements specify clear numerical thresholds, real-world eligibility often involves additional factors that our prescribers carefully evaluate. Patients with BMI slightly below 30 but with multiple weight-related health conditions may still qualify, particularly if previous weight management attempts have been unsuccessful. Conversely, some patients meeting the numerical BMI criteria may need additional medical evaluation before starting, especially those with certain gastrointestinal conditions or medication interactions.
Our clinical assessment process examines your complete health picture rather than relying solely on BMI calculations, ensuring that Wegovy represents an appropriate treatment choice for your individual circumstances. This personalised approach to interpreting Wegovy BMI requirements reflects current medical practice, where BMI serves as a useful guideline rather than an absolute determinant of treatment suitability.
Begin Your Wegovy Journey Today
Starting with Wegovy's 0.25mg dose at £79.99 represents an evidence-based approach to weight management for patients meeting BMI requirements. Use discount code FIRST40 at checkout for new customer savings, or DOSE25 for returning customers seeking to continue their treatment journey. Our clinical team remains available throughout your dose escalation period, providing guidance on managing any side effects and optimising your results. Visit https://everydaymeds.co.uk/products/wegovy-0-25mg to begin your assessment today, or explore our starter bundles for longer-term treatment planning. Every step of your journey is supported by our GPhC-registered pharmacy (#9012878), ensuring you receive both genuine medication and comprehensive clinical care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
